Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alaunos Therapeutics ( (TCRT) ) has issued an announcement.
On May 19, 2025, Alaunos Therapeutics, Inc. issued a warrant to Mast Hill Fund, L.P. to purchase 79,900 shares of its common stock, alongside an equity purchase agreement and a registration rights agreement. On June 9, 2025, the company amended the warrant to include a floor price of $0.57 per share, removed the requirement to adjust the number of shares issuable upon certain events, and eliminated certain rights of the warrant holder in connection with fundamental transactions.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 481,379
Technical Sentiment Signal: Sell
Current Market Cap: $4.97M
For detailed information about TCRT stock, go to TipRanks’ Stock Analysis page.